

METHOD AND APPARATUS FOR INHIBITING ATRIAL TACHYARRHYTHMIA THERAPY

5

FIELD OF THE INVENTION

10 The present invention relates generally to implantable medical devices and, more particularly, to implantable pacemakers and cardioverter-defibrillators for detecting and treating atrial tachyarrhythmias.

BACKGROUND OF THE INVENTION

15

20

Implantable cardioverter-defibrillators (ICDs) have been developed that employ detection algorithms capable of recognizing and treating atrial tachycardias and atrial fibrillation. In general, ICDs are designed to treat such tachycardias with antitachycardia pacing and low-energy cardioversion shocks in conjunction with back-up defibrillation therapy. These ICDs monitor the heart rate and the onset of the arrhythmia by sensing endocardial signals and determining when the heart is in need of either cardioversion to treat a given tachycardia or of defibrillation to treat a fibrillation condition.

25

Certain ICDs have been designed with dual chamber sensing capabilities to detect and analyze both ventricular and atrial endocardial signals. This increase in cardiac signal input to the ICD has provided an opportunity to determine the origin and the nature of atrial and ventricular tachyarrhythmia, and to reduce the frequency of inappropriate therapy being delivered to an implant patient.

30

However, while the combination of antitachycardia pacing with low and high energy shock delivery, as well as backup bradycardia pacing, in ICDs has expanded the number of clinical situations in which the devices may appropriately be employed,

improved means of coordinating atrial rate information in a way that results in a system that effectively and efficiently treats atrial tachyarrhythmias is still desired.

For the reasons stated above, and for other reasons stated below which will become apparent to those skilled in the art upon reading the present specification, there is a need in the art for improved atrial arrhythmia detection and therapy techniques. There exists a further need for such techniques that provide for enhanced detection and treatment of atrial arrhythmias under conditions of varying cardiac activity, such as occurs during exercise. The present invention fulfills these and other needs.

SUMMARY OF THE INVENTION

The present invention is directed to a system and method for inhibiting delivery of atrial therapy under certain conditions. In accordance with an embodiment of the present invention, inhibiting delivery of atrial therapy involves developing atrial intervals and ventricular intervals from sensed atrial and ventricular events, respectively. An average atrial rate and an average ventricular rate is developed from a predetermined number of the atrial and ventricular intervals, respectively. Delivery of atrial therapy is inhibited if the average atrial rate fails to exceed the average ventricular rate by at least a predetermined factor.

According to another embodiment of the present invention, atrial intervals and ventricular intervals are developed from sensed atrial and ventricular events, respectively. A representative atrial interval rate and a representative ventricular interval rate is calculated using a predetermined number of the atrial and ventricular intervals, respectively. An average atrial rate and an average ventricular rate is calculated using the representative atrial and ventricular interval rates, respectively. Delivery of atrial therapy is inhibited if the average atrial rate fails to exceed the average ventricular rate by at least a predetermined factor.

Calculating the average atrial and ventricular rates may involve calculating the average atrial and ventricular rates on a beat per minute basis using the representative atrial and ventricular interval rates. The predetermined number of the atrial and ventricular intervals used to calculate the average atrial and ventricular rates may range
5 between 4 and 60 of the most recent atrial and ventricular intervals, respectively, with a range between 5 and 20 representing a good sampling. In one embodiment, the predetermined number of atrial and ventricular intervals is about 10, respectively.

Delivery of atrial therapy, according to one embodiment of the present invention, is inhibited if the average atrial rate fails to exceed the average ventricular rate by a
10 predetermined factor of at least 105 percent, such as between 105 and 125 percent, with 115 percent being a useful percentage. Atrial therapy may, for example, be inhibited if the average atrial rate fails to exceed the average ventricular rate by at least a predetermined factor ranging between 10 and 30 beats per minute, such as 20 beats per minute. After inhibiting atrial therapy, the capability to deliver atrial therapy may be
15 subsequently enabled if the average atrial rate exceeds the average ventricular rate by at least the predetermined factor.

The representative atrial and ventricular interval rates may be computed by computing an average of a predetermined number of the atrial and ventricular intervals, respectively. The representative atrial and ventricular interval rates may also be
20 computed by computing a median of a predetermined number of the atrial and ventricular intervals, respectively. The representative atrial and ventricular interval rates may alternatively be computed by computing a mean of a predetermined number of the atrial and ventricular intervals, respectively.

According to an alternative approach, average atrial and ventricular rates are
25 developed based on a number of atrial and ventricular intervals respectively computed during a predetermined snapshot of time, rather than being based on a number n, m of the most recent atrial and ventricular intervals. The predetermined snapshot duration may range between about 2 seconds and 60 seconds, with a preferred range being between about 4 seconds and 30 seconds.

According to another embodiment of the present invention, a body implantable system includes at least one lead comprising atrial and ventricular electrodes. A detector, which is coupled to the lead, senses atrial events and ventricular events. A control circuit, coupled to the detector, calculates an average atrial rate and an average ventricular rate developed from a predetermined number of the atrial and ventricular intervals, respectively. The control circuit inhibits delivery of atrial therapy if the average atrial rate fails to exceed the average ventricular rate by at least a predetermined factor.

The control circuit may calculate the average atrial and ventricular rates on a beat per minute basis using an average, median or mean of the predetermined number of the atrial and ventricular intervals, respectively. The predetermined number of the atrial and ventricular intervals may range between 5 and 20 of the most recent atrial and ventricular intervals, respectively, with 10 representing a suitable predetermined factor.

The control circuit calculates the average atrial and ventricular rates preferably on a beat per minute basis using an average of the predetermined number of the atrial and ventricular intervals. The control circuit inhibits atrial therapy if the average atrial rate fails to exceed the average ventricular rate by at least a predetermined factor ranging between 10 and 30 beats per minute, such as 20 beats per minute. The predetermined factor may alternatively be expressed in terms of a ratio or percentage (e.g., such as a percentage between 105 percent and 125 percent). The control circuit enables the capability to deliver atrial therapy if the average atrial rate exceeds the average ventricular rate by at least the predetermined factor.

The above summary of the present invention is not intended to describe each embodiment or every implementation of the present invention. Advantages and attainments, together with a more complete understanding of the invention, will become apparent and appreciated by referring to the following detailed description and claims taken in conjunction with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a depiction of an implantable medical device with which the atrial therapy inhibiting methodologies of the present invention may be practiced;

Figure 2 is a block diagram of several components housed in the implantable medical device of Fig. 1;

Figure 3 is a flow chart depicting various processes of an atrial therapy inhibiting methodology in accordance with an embodiment of the present invention;

Figure 4 is a flow chart depicting various processes of an atrial therapy inhibiting methodology in accordance with another embodiment of the present invention;

Figure 5 is a flow chart depicting various processes of an atrial therapy inhibiting methodology in accordance with a further embodiment of the present invention; and

Figure 6 is a graphical depiction of a detection window that differentiates AAR/AVR ratios for which atrial thereby is or is not inhibited as a function of a predetermined bias factor.

While the invention is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail hereinbelow. It is to be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the invention is intended to cover all modifications, equivalents, and alternatives falling within the scope of the invention as defined by the appended claims.

DETAILED DESCRIPTION OF VARIOUS EMBODIMENTS

In the following description of the illustrated embodiments, references are made to the accompanying drawings which form a part hereof, and in which is shown by way of illustration, various embodiments in which the invention may be practiced. It is to be understood that other embodiments may be utilized, and structural and functional changes may be made without departing from the scope of the present invention.

Referring now to the figures, and more particularly to Fig. 1, there is shown a body implantable system 20 that represents one of several types of systems with which the atrial therapy inhibiting methodologies of the present invention may be practiced. For example, the implantable pulse generator 22 may be representative of all or part of a pacemaker, defibrillator, cardioverter, cardiac monitor, or re-synchronization device. Accordingly, the atrial therapy inhibiting methodologies of the present invention may be practiced in a wide variety of implantable medical devices that sense cardiac activity.

The body implantable system 20 is shown to include an implantable pulse generator 22 coupled to an atrial lead 24 and a ventricular lead 26. The system 20 may also include endocardial pacing and cardioversion/defibrillation leads (not shown) that are advanced into the coronary sinus and coronary veins to locate the distal electrode(s) adjacent to the left ventricle or the left atrium. The distal end of such coronary sinus leads is advanced through the superior vena cava, the right atrium, the valve of the coronary sinus, the coronary sinus, and into a coronary vein communicating with the coronary sinus, such as the great vein. Typically, coronary sinus leads do not employ any fixation mechanism and instead rely on the close confinement within these vessels to maintain each electrode at a desired site.

The system 20, as shown in Fig. 1, is implanted in a human body 28 with portions of the atrial and ventricular leads 24 and 26 inserted into a heart 30 to detect and analyze electric cardiac signals produced by both the atria 32 and the ventricles 34 of the heart 30. The atrial and ventricular leads 24 and 26 also provide electrical energy to the heart 30 under certain predetermined conditions to treat various types of

cardiac arrhythmia, including, for example, atrial and ventricular tachycardias, and atrial and ventricular fibrillation of the heart 30.

A block diagram of the implantable pulse generator 22 electronics is provided in Fig. 2. The implantable pulse generator 22 includes a housing 36 which contains, among other components, a controller 100 and memory 102, which typically includes read only memory (ROM) and random access memory (RAM). Pulse generator 22 further includes a detector 104, which includes atrial and ventricular sense amplifiers (not shown), a therapy delivery unit 106, and a telemetry unit 108. The electronic components of the pulse generator 22 are interconnected by way of a bus connection (not shown).

Power to the implantable pulse generator 22 is supplied by an electrochemical battery 114 which is contained within the implantable pulse generator housing 36. The implantable pulse generator 22 is interrogated and programmed via bi-directional radio frequency telemetry through cooperative operation between the telemetry unit 108 and an external programmer in a manner known in the art.

The atrial therapy inhibiting methodologies implemented by system 20 are embodied in one or more algorithms as firmware within memory 102, and are executed by the controller 100. The detector 104 is also connected to the controller 100, and contains a plurality of electrical connections 110 coupled to the atrial and ventricular sense amplifiers. The outputs of the sense amplifiers are connected to the controller 100, such that atrial and ventricular signals received through the detector 104 are analyzed by the algorithms implemented within the controller 100. The controller 100 is also coupled to the therapy delivery unit 106, which controls the delivery of electrical energy to the heart 30 through a plurality of electrical output connections 112 to affect the sinus rhythm of the heart 30 under certain combinations of atrial 32 and ventricular 34 conditions.

Referring again to Fig. 1, a connector block 38 is mounted on the implantable pulse generator 22. The connector block 38 has two connector ports for coupling the atrial lead 24 and the ventricular lead 26 to the detector 104 and the therapy delivery unit 106 of the implantable pulse generator 22. Additional connector ports can be

added to the connector block 38, as in the case of configurations having three or more ports as is known in the art. Alternatively, the connector block 38 can be provided with one connector port for coupling an implantable transvenous lead to the implantable pulse generator 22. It is understood that atrial and ventricular sensing and
5 pacing/defibrillating functions may be accomplished using a single lead system employing atrial and ventricular conductors/electrodes, rather than by use of the dual lead system shown in Fig. 1.

In general, the electrical activity in the heart 30 is sensed, and therapies are delivered to the heart 30, through at least one transvenous pacing/defibrillation lead
10 connected to the implantable pulse generator 22. Unipolar and/or bipolar pacing and sensing electrodes can be used in conjunction with the transvenous pacing/defibrillation lead. In the embodiment shown in Fig. 1, bipolar leads and sensing circuits are utilized for sensing both the atrial 32 and the ventricular 34 activity. Sensing atrial activity includes the determination of atrial P-waves for purposes of determining atrial intervals.
15 Ventricular activity is monitored by sensing for the occurrence of ventricular R-waves for purposes of determining ventricular intervals. Pacing therapies to the atrium 32 or ventricle 34 are delivered to the heart 30 using these same leads.

The system 20 may also employ defibrillation electrodes which are connected to the electrical output connections 112, and serve to deliver cardioversion and
20 defibrillation level electrical pulses to the heart 30 as determined by the programming of controller 100. The housing 36 of the system 20 may be used as an optional defibrillation electrode, where the housing 36 of the implantable pulse generator 22 is electrically connected to a cathode pole of the therapy delivery unit 106. All defibrillation electrical pulses are delivered to the heart with at least two defibrillation
25 electrodes, or through at least one defibrillation electrode and the housing 36 of the implantable pulse generator 22. The system 20 supports a plurality of pacing regimens.

In addition to the lead configuration shown in Fig. 1, the system 20 supports several other lead configurations and types. For example, it is possible to use ventricular epicardial rate sensing, atrial endocardial bipolar pace/sensing, ventricular

endocardial bipolar pace/sensing, epicardial patches, and ancillary leads in conjunction with the implantable pulse generator 22.

In the embodiment of system 20 depicted in Fig. 1, the atrial lead 24 has an elongated body 40 having a peripheral surface 42, proximal and distal ends, 44 and 46, a first atrial electrode 48, and a second atrial electrode 50 on the peripheral surface 42. The first atrial electrode 48 and the second atrial electrode 50 receive bipolar electrical cardiac signals from the right atrium chamber 52 of the heart 30, and are attached on the peripheral surface 42 of the elongated body 40.

The first atrial electrode 48 is situated at or adjacent to the distal end 46 of the elongated body 40 and is either a pacing tip electrode or a semi-annular or annular electrode partially or completely encircling the peripheral surface 42 of the elongated body 40. The second electrode 50 is an annular or semi-annular electrode encircling or partially encircling the peripheral surface 42 of the elongated body 40. The second electrode 50 is spaced longitudinally along the peripheral surface 40 from the first atrial electrode 48 and the distal end 46 of the atrial lead 24, such that when the atrial lead 24 is inserted into the right atrial chamber 52 of the heart 30, the first atrial electrode 48 is in physical contact with a portion of a wall of the right atrial chamber 52 of the heart 30 and the second electrode 50 is within the right atrium chamber 52.

Electrical conductors extend longitudinally within the elongated body 40 of the atrial lead 24 from a connection end at the proximal end 44 and make connection to the first and second atrial electrodes 48 and 50. The proximal end 44 of the atrial pacing lead 24 is attached to the connector block 38 of the implantable pulse generator 22. The connector block 38 provides electrical coupling between the contact ends of the electrical conductors of atrial lead 24 with the atrial sense amplifier of the detector 104 and the therapy delivery unit 106, such that the implantable pulse generator 22 receives bipolar signals from, and delivers bipolar pacing to, the right atrium 52 of the heart 30.

The ventricular lead 26 includes an elongated body 54 having a peripheral surface 56, proximal and distal ends, 58 and 60, and a ventricle pacing electrode 62. The ventricular lead 26 also includes a first defibrillation electrode 64 and a second defibrillation electrode 66 situated on the peripheral surface 56 of the elongated body

54. The ventricular pacing electrode 62 and the first defibrillation electrode 64 are adapted to receive electrical cardiac signals from the right ventricle chamber 68 of the heart 30, and are attached on the peripheral surface of the elongated body 54. The second defibrillation electrode 66 is spaced apart and longitudinally on the peripheral surface 56 of the ventricular lead 26. This configuration affords positioning of the ventricular lead 26 in the heart 30 with the ventricular pacing electrode 62 in the apex of the right ventricle 68, the first defibrillation electrode 64 within the right ventricle chamber of the heart, and the second defibrillation electrode 66 within the right atrium chamber 52 or a major vein leading to right atrium.

Electrical leads extend longitudinally within the elongated body 54 of the ventricular lead 26 from a connection end at the proximal end 58 to make connection with the ventricular pacing electrode 62, the first defibrillation electrode 64, and the second defibrillation electrode 66. The proximal end 58 of the ventricular lead 26 is attached to the connector block 38 of the implantable pulse generator 22. The connector block 38 provides for electrical coupling between the contact ends of the electrical conductors of ventricular lead 26 with the ventricular sense amplifier of the detector 104 and the therapy delivery unit 106, such that the implantable pulse generator 22 receives either unipolar or bipolar signals from, and can deliver unipolar or bipolar pacing to, the right ventricle 68 and defibrillation electrical pulses to the ventricles 34 of the heart 30.

The atrial lead 24 and the ventricular lead 26 are attached to, and are separated from, the implantable pulse generator 22 to facilitate insertion of the atrial lead 24 into the heart 30. The proximal end 44 of the atrial lead 24 and the proximal end 58 of the ventricular lead 26 are adapted to seal together with the connector ports of the implantable pulse generator 22 to thereby engage the contact ends of the atrial lead 24 and the ventricular lead 26 with the plurality of electrical connections 110 and the therapy delivery unit 106 of the implantable pulse generator 22. The implantable pulse generator 22 of the system 20 is then positioned subcutaneously within the body 28.

Referring now to Fig. 3, there is shown in flow diagram form several processes of an atrial therapy inhibiting methodology implemented by system 20 in accordance with

an embodiment of the present invention. An atrial therapy inhibiting methodology of the present invention evaluates a series of atrial intervals and ventricular intervals to ensure that atrial therapy, although indicated as potentially being needed or appropriate by the evaluation, is inhibited or withheld under certain conditions.

5 One condition of particular concern involves an increase in the rate of both atrial and ventricular events at approximately the same rate, such as occurs during exercise. In such a case, the ratio of atrial intervals relative to ventricular intervals (A:V) is normally about 1:1, notwithstanding the increased atrial and ventricular event rate.

10 In cases in which A:V ratios of about 1:1 are detected, it has been determined that atrial therapy should be inhibited or withheld. In one embodiment, for example, if the atrial rate fails to exceed the ventricular rate by a predetermined factor, referred to herein as a bias factor, atrial therapy is inhibited. The atrial detection enhancement of the present invention may thus be viewed as a "detection inhibitor."

15 Detection and response decisions made by the system 20 are based on detected cardiac events and computed event intervals. As is shown in Fig. 3, atrial and ventricular events are detected 200, 202 from which atrial and ventricular intervals are developed 204 in a manner known in the art.

20 Detection 200 of atrial events typically involves sensing of atrial P-waves. An atrial interval (e.g., an A-A wave time interval) is computed 204 using the detected atrial P-waves. In a similar manner, detection 202 of ventricular events typically involves sensing of ventricular R-waves. A ventricular interval (e.g., an R-R wave time interval) is computed 204 using the detected ventricular R-waves.

25 An atrial rate (AR) is calculated 206 using the computed atrial intervals. A ventricular rate (VR) is calculated 208 using the computed ventricular intervals. The atrial and ventricular rates are evaluated to determine if the atrial and ventricular rhythms are approximately equal. In one embodiment, a ratio of atrial rates relative to ventricular rates is computed. If this AR:VR ratio indicates 210 the presence of a 1:1 rhythm condition, any atrial therapy that may otherwise appear to be appropriate under present conditions is withheld 212.

If the AR:VR ratio indicates 210 that a 1:1 rhythm condition is not present, and further that the atrial rate exceeds the ventricular rate by a selected bias factor, then an atrial therapy that may be appropriate under present conditions is not withheld (i.e., not inhibited). In this scenario, other atrial detection procedures, if enabled, are typically invoked to determine if atrial therapy should be delivered or withheld, or which atrial therapy should be delivered.

By way of example, a dual atrial and ventricular windowing methodology for detecting and verifying atrial arrhythmias is disclosed in commonly-owned U.S. patent application entitled "Atrial and Ventricular Tachyarrhythmia Detection System and Method," filed under Attorney Docket No. 1275.7US01, which is hereby incorporated herein by reference. This or other known atrial arrhythmia detection methodologies may be employed in combination with the present invention to determine if and when atrial therapy should be delivered or withheld, or which atrial therapy should be delivered.

Figure 4 illustrates in flow diagram form several processes of an atrial therapy inhibiting methodology implemented by system 20 in accordance with another embodiment of the present invention. As in the previously discussed illustrative embodiment, detection and response decisions made by the system 20 are based on detected cardiac events and computed event intervals. In particular, atrial and ventricular events are detected 230, 232 from which atrial and ventricular intervals are developed 234.

In accordance with this embodiment, an average atrial rate (AAR) is calculated 236 using a set of the computed atrial intervals. The number of atrial intervals used to calculate the average atrial rate may range between about 4 and 60 of the most recent atrial intervals, with a preferred range being between about 5 and 20 of the most recent atrial intervals. For example, the number of atrial intervals used to calculate the average atrial rate may be a number up to about 10 of the most recent atrial intervals. An average atrial rate is computed by employing a known averaging algorithm, which is applied to this set of n most recent atrial intervals.

An average ventricular rate (AVR) is calculated 238 using a set of the computed ventricular intervals. The number of ventricular intervals used to calculate the average ventricular rate may range between about 4 and 60 of the most recent ventricular intervals, with a preferred range being between about 5 and 20 of the most recent
5 ventricular intervals. For example, the number of ventricular intervals used to calculate the average ventricular rate may be a number up to about 10 of the most recent ventricular intervals. An average ventricular rate is computed using a known averaging algorithm operating on this set of m most recent ventricular intervals.

In one approach, an equal number of interval samples are used to calculate the
10 respective average atrial and ventricular interval rates (i.e., $n = m$). For example, 10 of the most recent atrial and ventricular intervals can be used to calculate the respective average atrial and ventricular interval rates. In an alternative approach, the number of interval samples used to calculate the respective average atrial and ventricular interval rates may differ. For example, a set of n most recent atrial interval samples can be
15 used to calculate the average atrial interval rate, while a set of m most recent ventricular atrial interval samples can be used to calculate the average ventricular interval rate, where n and m represent different integers (e.g., $n = 15$ and $m = 10$ or $n = 12$ and $m = 8$, for example).

According to an alternative approach, average atrial and ventricular rates are
20 developed based on a number of atrial and ventricular intervals respectively computed during a predetermined snapshot of time, rather than being based on a number n, m of the most recent atrial and ventricular intervals. The predetermined snapshot duration may range between about 2 seconds and 60 seconds, with a preferred range being between about 4 seconds and 30 seconds.

For example, the average atrial rate may be computed based on a number n of
25 atrial intervals computed during the last x seconds (e.g., a snapshot of atrial intervals computed the during the last $x = 15$ seconds). The average ventricular rate may be computed based on a number m of ventricular intervals computed during the last y seconds, where the time durations x and y are typically the same, but may be different
30 (e.g., a snapshot of ventricular intervals computed the during the last $y = 15$ seconds).

The relationship (e.g., ratio) between average atrial and ventricular rates is developed using the number n, m of respective atrial and ventricular intervals captured during the predefined snapshot duration.

In accordance with a further embodiment, the average atrial and ventricular rates are developed based on atrial and ventricular time durations associated with detection of a predetermined number of the most recent atrial and ventricular intervals. For example, an atrial time duration, x, is determined as the amount of time associated with detection of the most recent n atrial intervals. A ventricular time duration, y, is determined as the amount of time associated with detection of the most recent m ventricular intervals. The relationship (e.g., ratio) between average atrial and ventricular rates is developed using the atrial and ventricular time durations, y and x.

The average atrial and ventricular rates are used, together with a bias factor (BF), in the process of determining whether to inhibit atrial therapy under present conditions. The bias factor, BF, is a programmable value that can be adjusted based on a desired level of sensitivity or insensitivity to detection of differences between atrial and ventricular rates. For example, adjusting the bias factor, BF, effectively adjusts a threshold that demarcates the ratio of the average atrial and ventricular rates (i.e., AAR:AAV) from a 1:1 AAR to AVR ratio. In other words, the bias factor, BF, may be adjusted so that the atrial tachyarrhythmia detection enhancement of the present invention is less sensitive to potential atrial oversensing and undersensing.

As is further shown in Fig. 4, the average atrial rate is compared to the average ventricular rate plus the predetermined bias factor. In formulaic terms, the value of AAR is compared to the value of AVR + BF. If the average atrial rate is less than or equal to the average ventricular rate plus the predetermined bias factor (i.e., if $AAR \leq AVR + BF$), then atrial therapy is inhibited. In this case, the present AAR to AVR ratio has exceeded the preestablished AAR to AVR ratio threshold. In other words, the system, under these conditions, has detected an AAR to AVR ratio that is undesirably close to a 1:1 rhythm condition.

Atrial therapy is not inhibited (e.g., is enabled for invocation) if the average atrial rate is greater than the average ventricular rate plus the predetermined bias factor

(i.e., if $AAR > AVR + BF$). Under conditions in which atrial therapy is not inhibited 244, other atrial detection procedures, if enabled, are typically invoked to determine if atrial therapy should ultimately be delivered or withheld, or which atrial therapy should be delivered.

5 Figure 6 graphically illustrates the effect of the bias factor, BF, on detection sensitivity or insensitivity to differences between average atrial and ventricular rates. The graph of Fig. 6 has an x axis representing increasing average ventricular rates (V Rate) and a y axis representing increasing average atrial rates (A Rates). The line identified by label A represents equivalency between average atrial and ventricular
10 rates (i.e., a 1:1 AAR to AVR ratio or a 1:1 rhythm condition).

As the average atrial rate increases relative to the average ventricular rate, as is the case in region B in Fig. 6, the ratio of AAR to AVR increases above the 1:1 AAR/AVR ratio. The region B, defined between lines A and E, depicts a bias factor window. The bias factor window defines a region B in which atrial therapy is either
15 inhibited or not inhibited for ratios of AAR to AVR that exceed 1:1 above a predefined threshold, such as a predefined SVT threshold or other atrial arrhythmia threshold.

For ratios of AAR to AVR falling in region C, and assuming that the SVT or other atrial arrhythmia threshold is exceeded, the average atrial rate does not exceed the average ventricular rate. As such, atrial therapy is inhibited for ratios of AAR to AVR
20 falling in region C.

For ratios of AAR to AVR falling in region D, and assuming that the SVT other atrial arrhythmia threshold is exceeded, the average atrial rate exceeds the average ventricular rate by at least the predetermined bias factor, BF. As such, atrial therapy is not inhibited for ratios of AAR to AVR falling in region D. In this case, the AAR to AVR
25 ratio is sufficiently distant from the 1:1 AAR/AVR ratio.

However, for ratios of AAR to AVR falling in region B, and again assuming that the SVT other atrial arrhythmia threshold is exceeded, the average atrial rate does not exceed the average ventricular rate by at least the predetermined bias factor, BF. In this case, an inhibit threshold, I_{TH} , which is represented as dashed line E in Fig. 6, has
30 not been exceeded. The inhibit threshold, I_{TH} , can, for example, be characterized by

the equation $I_{TH} = (AAR + BF) / AVR$. Accordingly, atrial therapy is inhibited for ratios of AAR to AVR falling in region B. In this case, the AAR to AVR ratio is not sufficiently distant from the 1:1 AAR/AVR ratio.

Figure 5 illustrates several processes of an atrial therapy inhibiting methodology implemented by system 20 in accordance with a further embodiment of the present invention. As in the previously discussed illustrative embodiments, detection and response decisions made by the system 20 are based on detected cardiac events and computed event intervals. Atrial and ventricular events are detected from which atrial and ventricular intervals are developed 260.

In accordance with this embodiment, a "representative" atrial interval rate is computed 262 using a predetermined number of atrial interval samples. The predetermined number of atrial intervals used to calculate the representative atrial interval rate may range between 4 and 60 of the most recent atrial intervals, with between 5 and 20 of the most recent atrial intervals representing a preferred range, and 10 of the most recent atrial intervals representing a suitable sampling within this preferred range.

The representative atrial interval rate, in one embodiment, represents an "average" of the set of n most recent atrial interval samples. Various types of averaging algorithms can be employed. For example, the representative atrial interval rate can be computed by determining the arithmetic or weighted average of the set of n most recent atrial interval samples. Alternatively, the representative atrial interval rate may be computed as the mean of the set of n most recent atrial interval samples. The representative atrial interval rate may, for example, represent the arithmetic mean, geometric mean or harmonic mean of the set of n most recent atrial interval samples.

The representative atrial interval rate may alternatively be computed as the median of the set of n most recent atrial interval samples. Also, averaging techniques that employ standard deviation computations may also be used to compute the representative atrial interval rate, such as those employing one, two or three sigma computations for excluding statistically aberrant atrial interval rate samples from

consideration. Averaging techniques that exclude the longest, shortest, or both longest and shortest of the set of n most recent atrial interval samples may also be employed.

A "representative" ventricular interval rate is computed 264 using a predetermined number of ventricular interval samples. The predetermined number of ventricular intervals used to calculate the representative ventricular interval rate may range between about 5 and 20 of the most recent ventricular intervals, with 10 of the most recent ventricular intervals representing a suitable sampling. The predetermined number of ventricular and atrial intervals used to respectively compute the representative ventricular and atrial interval rates may represent the same or different number of samples.

The representative ventricular interval rate represents an "average" of the set of m most recent ventricular interval samples. The representative ventricular interval rate can, for example, be computed using the approaches described above with respect to computing a representative atrial interval rate.

An average atrial rate is calculated 266 using the representative atrial interval rate. The average atrial rate, according to this illustrative embodiment, is preferably expressed in terms of beats per minute (bpm). In this case, the representative atrial interval rate is converted to an average atrial rate expressed in terms of beats per minute using known techniques.

An average ventricular rate is calculated 268 using the representative ventricular interval rate. The average ventricular rate, according to this illustrative embodiment, is converted to an average ventricular rate expressed in terms of beats per minute using known techniques.

The calculated average atrial and ventricular rates are used, together with a predetermined bias factor, to determine whether or not to inhibit atrial therapy. The value of the bias factor, BF, is programmable in the ranges of 5-30 bpm, where 20 bpm is an appropriate number. The average atrial rate is compared 270 to the average ventricular rate plus the predetermined bias factor. In other words, the value of AAR is compared to the value of $AVR + BF$. If 272 the average atrial rate is less than or equal

to the average ventricular rate plus the predetermined bias factor (i.e., if $AAR \leq AVR + BF$), then atrial therapy is inhibited 274.

Atrial therapy is not inhibited 276 if the average atrial rate is greater than the average ventricular rate plus the predetermined bias factor (i.e., if $AAR > AVR + BF$).

5 As was discussed previously, other atrial detection procedures are typically invoked to determine if atrial therapy should ultimately be delivered or withheld, or which atrial therapy should be delivered.

The predetermined bias factor, BF, may be expressed in various forms. In the illustrative embodiment described above, for example, the predetermined bias factor, BF, is expressed in terms of a specified number of beats per minute, such as 20 beats per minute. The predetermined bias factor, BF, may alternatively be expressed in terms of percentages. For example, the predetermined bias factor, BF, may be programmed to represent a percentage between 105 and 125 percent. Atrial therapy can be inhibited, for example, if the average atrial rate fails to exceed the average ventricular rate by at least the predetermined percentage, such as by at least 115 percent.

The atrial therapy inhibiting methodology of the present invention may be employed in a detection approach that utilizes rate zone detection algorithms. In accordance with a further embodiment of the present invention, the system 20 can be programmed to define a number of different rate zones for classifying atrial and ventricular interval rates. The number of atrial and ventricular rate zones typically differ, but may be the same. For example, ventricular interval rates may be classified using one, two or three ventricular rate zones. Atrial interval rates are typically classified using one or two atrial rate zones.

25 In general, a number of rate zones are defined to classify atrial and ventricular interval rates that are above a defined upper limit for normal atrial and ventricular interval rates, respectively. A rate zone is a range of atrial or ventricular interval rates that has an associated lower rate threshold. Typically, a given rate zone is defined by its lower rate threshold and that of an adjacent rate zone (e.g., next higher rate zone).

30 For each rate zone, the lower rate threshold is a programmable value in beats per

minute (bpm) and is the value to which the system 20 compares each sensed atrial or ventricular interval rate in order to determine the zone in which that atrial or ventricular interval rate belongs.

In one embodiment, ventricular rate zones can be defined for slow ventricular tachycardia (VT-1), fast ventricular tachycardia (VT), and ventricular fibrillation (VF). Atrial rate zones can be defined to classify supraventricular tachycardia (SVT) and atrial fibrillation (AF). The lower rate threshold for each of the atrial and ventricular rate zones may be programmed at a given beat-per-minute as is appropriate.

According to one approach, to determine if an individual atrial or ventricular interval rate falls into a particular programmed rate zone, the system 20 detects the intervals between a series of the most recent consecutive atrial P-waves or ventricular R-waves. Detecting the intervals between 40 of the most recent consecutive atrial P-waves and 10 of the most recent consecutive ventricular R-waves, for example, is considered to be a good sampling.

These atrial and ventricular samplings may be referred to as detection windows, with a new atrial and ventricular detection window occurring with each consecutive atrial P-wave and ventricular R-wave, respectively. The lengths of the atrial and ventricular detection windows, in the above example, are 40 and 10 samples, respectively. The length of the atrial and ventricular windows may be varied, such as between 20-60 and 5-15 samples, for example.

The system assesses the atrial and ventricular intervals in relation to one or more of the predefined atrial and ventricular rate zones, respectively. The use of atrial and ventricular detection windows helps to differentiate and classify atrial and ventricular tachyarrhythmias into a predefined rate zone, and helps to ensure that the correct atrial or ventricular therapy is delivered to the patient.

The atrial therapy inhibiting methodologies of the present invention may be implemented for each of the predefined rate zones according to this embodiment. For example, the atrial therapy inhibiting methodologies of the present invention may be implemented in the context of various types of atrial or ventricular tachyarrhythmia detection processes, including those that employ rate zone differentiation, such as

those disclosed in commonly owned U.S. Patent No. 5,978,707 and U.S. patent application entitled "Atrial and Ventricular Tachyarrhythmia Detection System and Method," filed under Attorney Docket No. 1275.7US01, both of which are hereby incorporated herein by reference in their respective entireties.

5 It will, of course, be understood that various modifications and additions can be made to the preferred embodiments discussed hereinabove without departing from the scope of the present invention. Accordingly, the scope of the present invention should not be limited by the particular embodiments described above, but should be defined only by the claims set forth below and equivalents thereof.

10

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209